Vol. 18 No. 1, January 2014

Index

• Diagnostic patents at the Supreme Court.
• Forward-looking view of healthcare innovation, from a leading life science venture capitalist.
• The increasing importance of biologics-based drugs in pharmaceutical pipelines.
• Need for new IP approaches to facilitate collaborative (academic-industrial) drug development.
• New business models to find cures and lower healthcare costs: a role for drug repurposing.
• Repurposing & collaborative drug development for rare diseases.
• The future of clinical trials: more transparency and pharmacogenomics.
• Implications of genomics advances for drug discovery, clinical therapies, & rare disease research.
• Intellectual property rights (IPR) in collaborative drug development in the EU: helping a European public-private partnership deliver - the need for a flexible approach to IPR.
• A new framework for assessing clinical data transparency initiatives.
• A new framework for assessing clinical data transparency initiatives.
• Ancillary orders of compulsory licensing and their compatibility with the TRIPs Agreement.
• The new era of biologic regulation and patenting under the America Invents Act.
• Repurposing - finding new uses for old (and patented) drugs: bridging the "Valley of Death," to translate academic research into new medicines.
• Trademarks under the North American Free Trade Agreement (NAFTA), with references to the current Mexican law.
• Territoriality challenges in protecting trademark interests in the system of generic top-level domains (gTLDs).
• How media got the biggest bite of (the) Apple: a look at the media misperception in the Apple-Samsung case.